Short Interest in Health Catalyst, Inc. (NASDAQ:HCAT) Grows By 15.8%

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 1,760,000 shares, an increase of 15.8% from the March 31st total of 1,520,000 shares. Based on an average trading volume of 616,300 shares, the days-to-cover ratio is currently 2.9 days.

Health Catalyst Stock Performance

NASDAQ:HCAT traded up $0.31 during mid-day trading on Monday, hitting $6.34. 926,109 shares of the company's stock traded hands, compared to its average volume of 620,095. The firm has a market capitalization of $371.27 million, a price-to-earnings ratio of -3.02 and a beta of 1.29. The firm has a 50 day moving average of $7.32 and a two-hundred day moving average of $8.23. The company has a current ratio of 4.42, a quick ratio of 4.42 and a debt-to-equity ratio of 0.62. Health Catalyst has a 12 month low of $5.45 and a 12 month high of $14.37.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.06. Health Catalyst had a negative net margin of 39.92% and a negative return on equity of 12.19%. The business had revenue of $75.08 million during the quarter, compared to analyst estimates of $73.67 million. On average, equities analysts forecast that Health Catalyst will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of HCAT. Impax Asset Management Group plc increased its stake in Health Catalyst by 52.0% in the fourth quarter. Impax Asset Management Group plc now owns 1,754,475 shares of the company's stock valued at $16,246,000 after acquiring an additional 600,000 shares during the period. Primecap Management Co. CA grew its stake in shares of Health Catalyst by 86.3% in the 3rd quarter. Primecap Management Co. CA now owns 1,120,438 shares of the company's stock valued at $11,339,000 after purchasing an additional 519,004 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Health Catalyst by 124.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 854,896 shares of the company's stock valued at $8,652,000 after purchasing an additional 473,323 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Health Catalyst by 437.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 253,368 shares of the company's stock worth $2,346,000 after buying an additional 206,184 shares in the last quarter. Finally, Nepsis Inc. lifted its position in shares of Health Catalyst by 20.5% during the 4th quarter. Nepsis Inc. now owns 1,091,932 shares of the company's stock worth $10,111,000 after buying an additional 186,128 shares during the period. Institutional investors own 85.00% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Piper Sandler reissued an "overweight" rating and issued a $15.00 target price (down from $17.00) on shares of Health Catalyst in a research report on Friday, February 23rd. Guggenheim raised shares of Health Catalyst from a "neutral" rating to a "buy" rating and set a $14.00 target price on the stock in a research report on Friday, January 26th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Wednesday, April 10th. Barclays assumed coverage on Health Catalyst in a research note on Wednesday, January 3rd. They set an "overweight" rating and a $14.00 price target for the company. Finally, Canaccord Genuity Group cut their price objective on Health Catalyst from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $12.10.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.